We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$322M
AUM Growth
-$34.8M
Cap. Flow
-$3.33M
Cap. Flow %
-1.03%
Top 10 Hldgs %
62.73%
Holding
76
New
14
Increased
20
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$14.9M
2
GSK icon
GSK
GSK
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
4
NVST icon
Envista
NVST
+$8.88M
5
DXCM icon
DexCom
DXCM
+$6.92M

Top Sells

Rank Stock Value
1
RCM icon
R1 RCM Inc. Common Stock
RCM
+$23.3M
2
EHTH icon
eHealth
EHTH
+$12.3M
3
RDUS icon
Radius Health, Inc.
RDUS
+$8.96M
4
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.38M
5
NUVA
NuVasive, Inc.
NUVA
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 90.47%
2 Real Estate 4.59%
3 Industrials 2.01%
4 Communication Services 1.04%
5 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GSK icon
1
GSK
GSK
$99.4B
$42.3M 13.13%
786,468
+231,520
+42% +$11.9M
2018 Q1
6 quarters
ENSG icon
2
The Ensign Group
ENSG
$10.4B
$27.8M 8.64%
627,155
+300,594
+92% +$14.9M
2017 Q4
7 quarters
DHR icon
3
Danaher
DHR
$161B
$25.8M 8.02%
201,578
+37,901
+23% +$4.75M
2018 Q3
4 quarters
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$25.8M 8%
643,818
+107,024
+20% +$4.93M
2017 Q4
7 quarters
ASND icon
5
Ascendis Pharma A/S
ASND
$14.9B
$22.8M 7.06%
236,392
+99,995
+73% +$11.2M
2017 Q4
7 quarters
AMRN icon
6
Amarin Corp
AMRN
$241M
$20.2M 6.25%
66,485
-11,418
-15% -$3.99M
2018 Q1
6 quarters
SNY icon
7
Sanofi
SNY
$96.6B
$11.1M 3.45%
240,000
-26,062
-10% -$1.12M
2017 Q4
7 quarters
RDUS icon
8
DELISTED
Radius Health, Inc.
RDUS
$8.88M 2.75%
344,698
-365,819
-51% -$8.96M
2017 Q4
7 quarters
NVST icon
9
Envista
NVST
$3.74B
$8.87M 2.75%
+318,000
New +$8.88M
2019 Q3
0 quarters
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$129B
$8.63M 2.68%
50,909
-6,940
-12% -$1.23M
2017 Q4
7 quarters
ILMN icon
11
Illumina
ILMN
$39.4B
$8.14M 2.52%
27,499
+8,697
+46% +$2.56M
2019 Q2
1 quarter
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.6B
$7.4M 2.3%
92,040
+4,900
+6% +$388K
2019 Q2
1 quarter
BOLD icon
13
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.13M 2.21%
253,726
+94,200
+59% +$3.21M
2019 Q2
1 quarter
DXCM icon
14
DexCom
DXCM
$33.2B
$6.65M 2.06%
+178,200
New +$6.92M
2019 Q3
0 quarters
RCM icon
15
DELISTED
R1 RCM Inc. Common Stock
RCM
$6.48M 2.01%
725,972
-1,973,187
-73% -$23.3M
2017 Q4
7 quarters
ABMD
16
DELISTED
Abiomed Inc
ABMD
$5.33M 1.65%
+29,950
New +$6.47M
2019 Q3
0 quarters
OHI icon
17
Omega Healthcare
OHI
$13.8B
$4.45M 1.38%
106,500
+65,100
+157% +$2.54M
2019 Q2
1 quarter
TGTX icon
18
TG Therapeutics
TGTX
$8.39B
$4.34M 1.35%
773,501
-110,000
-12% -$767K
2018 Q1
6 quarters
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.26M 1.32%
+256,000
New +$3.54M
2019 Q3
0 quarters
TLGT
20
DELISTED
Teligent, Inc
TLGT
$4.2M 1.3%
442,422
+183,934
+71% +$1.45M
2017 Q4
7 quarters
ARGX icon
21
argenx
ARGX
$51.9B
$4.1M 1.27%
36,004
-12,260
-25% -$1.66M
2017 Q4
7 quarters
LTC icon
22
LTC Properties
LTC
$2.35B
$3.55M 1.1%
69,327
+36,300
+110% +$1.75M
2019 Q2
1 quarter
SBRA icon
23
Sabra Healthcare REIT
SBRA
$4.96B
$3.54M 1.1%
154,100
+75,500
+96% +$1.61M
2019 Q2
1 quarter
MODN icon
24
DELISTED
MODEL N, INC.
MODN
$3.35M 1.04%
+120,695
New +$3M
2019 Q3
0 quarters
CTRE icon
25
CareTrust REIT
CTRE
$8.66B
$3.26M 1.01%
137,464
+75,000
+120% +$1.76M
2017 Q4
7 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Eversept Partners held 76 positions worth $322M, down 9.7% from $357M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners's Q3 2019 filing shows 14 new, 20 increased, 18 reduced and 19 closed positions. Its largest new stake was Envista: 318,000 shares worth $8.87M. The largest sale was R1 RCM Inc. Common Stock, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Real Estate and Industrials.

  • Eversept Partners's largest Q3 2019 buy was Envista: 318,000 shares worth $8.87M.
  • Eversept Partners added most to The Ensign Group in Q3 2019, an estimated $14.9M increase.
  • Eversept Partners's biggest Q3 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $23.3M.
  • Eversept Partners fully exited NuVasive, Inc. in Q3 2019, selling an estimated $5.37M.
  • Eversept Partners's ten largest holdings make up 63% of its $322M portfolio in Q3 2019.
  • Eversept Partners opened 14 new positions and closed 19 in Q3 2019.
  • Eversept Partners's portfolio value fell 9.7% quarter-over-quarter to $322M.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.